GT Biopharma

GT Biopharma(GTBP)

SAN FRANCISCO, CA
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Antioxidant Therapeutics, Antibodies

GT Biopharma is a life sciences company focused on Antioxidant Therapeutics, Antibodies.

Metabolic DiseasesOncology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Side-to-side anastomosis duodeno-ileostomy diversion procedure
Obesity
N/A
Clinical Trials (1)
NCT05322122Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System
N/A
MAGNET System, DI Biofragmentable
Obesity
N/A
Clinical Trials (1)
NCT07085741Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System in Mexico
N/A
N/A
Clinical Trials (1)
NCT04427384Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
N/A
N/A
Clinical Trials (1)
NCT07317076GT Metabolic Magnet System in Adults With Gastrointestinal Disorders
N/A
Magnet System, DI Biofragmentable
Obesity
N/A
Clinical Trials (1)
NCT06232746Magnetic Jejuno-Ileal Diversion Study ("MJI Study")
N/A
N/A
Clinical Trials (1)
NCT07431723Creation of Compression Anastomosis Using the GT Metabolic Magnet System
N/A
GTU Artificial Urinary Sphincter
Male Stress Urinary Incontinence
N/A
Clinical Trials (1)
NCT02288455Clinical Investigation of GT UrologIcal, LLC's Artificial Urinary Sphincter (RELIEF II)
N/A
Side-to-side duodenal-ileal anastomosis
Anastomosis, Surgical
N/A
Clinical Trials (1)
NCT06928545MagDI U.S. Registry
N/A
MAGNET System, DI Bio-fragmentable
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT05692518MagDI Diversion Feasibility Study
N/A
GammaTile seed loader
Central Nervous System Lesion
N/A
Clinical Trials (1)
NCT03088579Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device
N/A
Magnet System, DI Biofragmentable
Obesity
N/A
Clinical Trials (1)
NCT06613711MagDI Italian Study
N/A
MagGJ System
Obesity
N/A
Clinical Trials (1)
NCT06073457Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")
N/A
Magnet System, DI Biofragmentable
Obesity
N/A
Clinical Trials (1)
NCT06473831MagDI Australia Study
N/A
Magnet System, DI Biofragmentable
Obesity
N/A
Clinical Trials (1)
NCT06613724Magnetic Duodeno-Ileal Chile Study
N/A
Magnet System, DI Biofragmentable
Obesity
N/A
Clinical Trials (1)
NCT06467955MagDI Canada Study
N/A
Magnet System
Obesity (Disorder)
N/A
Clinical Trials (1)
NCT07317115Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
N/A
GTB-3550 TriKE® Phase I
High-risk Myelodysplastic Syndromes
Phase 1/2
Clinical Trials (1)
NCT03214666GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Phase 1/2
Phase 2
Clinical Trials (1)
NCT04690348Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
Phase 2
GammaTile®
Glioblastoma
Phase 3
Clinical Trials (1)
NCT07195591Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Phase 3
Gamma Tile-Surgically Targeted Radiation Therapy
Brain Metastases
Phase 3
Clinical Trials (1)
NCT04365374Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Phase 3
Gamma Tile-Surgically Targeted Radiation Therapy
Glioblastoma
Phase 4
Clinical Trials (1)
NCT05900908Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy
Phase 4
Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol
Glioblastoma
Phase 4
Clinical Trials (1)
NCT05342883GammaTile and Stupp in Newly Diagnosed GBM
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 1999
Portfolio: 22 clinical trials
SEC Filings: 2 available

Financials (FY2025)

R&D Spend
$6M10%
Net Income
-$13M
Cash
$4M
Source: SEC 10-K Filing